百奥赛图IPO:研发投入缩水、专职研发人员骤降至仅剩5人,专利待审、关联交易等问题受关注

金融界
22 Jul

百奥赛图(北京)医药科技股份有限公司(以下简称“百奥赛图”)主要聚焦于临床前CRO服务以及抗体药物的研发业务。2023年6月,该公司向上海证券交易所提交的科创板上市申请获得受理。在2024年1月完成首轮审核问询后,直至2025年6月底,百奥赛图将第二轮审核问询回复文件以及第三版招股说明书挂网公示。随着招股说明书、问询函等信息披露,市场发现,尽管百奥赛图在2020年至2023年期间累计亏损达...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10